BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37133743)

  • 1. A novel CDK4/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma.
    Zuo P; Li Y; Wang T; Lin X; Wu Z; Zhang J; Liao X; Zhang L
    J Neurooncol; 2023 May; 163(1):159-171. PubMed ID: 37133743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
    Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
    EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a machine learning algorithm for predicting diffuse midline glioma, H3 K27-altered, H3 K27 wild-type high-grade glioma, and primary CNS lymphoma of the brain midline in adults.
    Lv K; Chen H; Cao X; Du P; Chen J; Liu X; Zhu L; Geng D; Zhang J
    J Neurosurg; 2022 Dec; ():1-9. PubMed ID: 36681946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.
    Rechberger JS; Bouchal SM; Power EA; Nonnenbroich LF; Nesvick CL; Daniels DJ
    Expert Opin Ther Targets; 2023; 27(11):1071-1086. PubMed ID: 37897190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies.
    Findlay IJ; De Iuliis GN; Duchatel RJ; Jackson ER; Vitanza NA; Cain JE; Waszak SM; Dun MD
    Oncogene; 2022 Jan; 41(4):461-475. PubMed ID: 34759345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiosensitisation by olaparib through focused ultrasound delivery in a diffuse midline glioma model.
    't Hart E; Bianco J; Bruin MAC; Derieppe M; Besse HC; Berkhout K; Chin Joe Kie LA; Su Y; Hoving EW; Huitema ADR; Ries MG; van Vuurden DG
    J Control Release; 2023 May; 357():287-298. PubMed ID: 37019285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diffuse midline glioma].
    Saito R
    No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
    Vitanza NA; Biery MC; Myers C; Ferguson E; Zheng Y; Girard EJ; Przystal JM; Park G; Noll A; Pakiam F; Winter CA; Morris SM; Sarthy J; Cole BL; Leary SES; Crane C; Lieberman NAP; Mueller S; Nazarian J; Gottardo R; Brusniak MY; Mhyre AJ; Olson JM
    Neuro Oncol; 2021 Mar; 23(3):376-386. PubMed ID: 33130903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo.
    Brown EJ; Balaguer-Lluna L; Cribbs AP; Philpott M; Campo L; Browne M; Wong JF; Oppermann U; Carcaboso ÁM; Bullock AN; Farnie G
    Sci Rep; 2024 Jan; 14(1):328. PubMed ID: 38172189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. H3K27-altered diffuse midline glioma: a paradigm shifting opportunity in direct delivery of targeted therapeutics.
    Rechberger JS; Power BT; Power EA; Nesvick CL; Daniels DJ
    Expert Opin Ther Targets; 2023 Jan; 27(1):9-17. PubMed ID: 36744399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth.
    Madhavan K; Balakrishnan I; Lakshmanachetty S; Pierce A; Sanford B; Fosmire S; Elajaili HB; Walker F; Wang D; Nozik ES; Mitra SS; Dahl NA; Vibhakar R; Venkataraman S
    Clin Cancer Res; 2022 Jun; 28(11):2409-2424. PubMed ID: 35344040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
    López-Pérez CA; Franco-Mojica X; Villanueva-Gaona R; Díaz-Alba A; Rodríguez-Florido MA; Navarro VG
    J Neurooncol; 2022 Jul; 158(3):369-378. PubMed ID: 35567713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
    Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
    Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
    Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
    Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive profiling of stem-like features in pediatric glioma cell cultures and their relation to the subventricular zone.
    Da-Veiga MA; Coppieters N; Lombard A; Rogister B; Neirinckx V; Piette C
    Acta Neuropathol Commun; 2023 Jun; 11(1):96. PubMed ID: 37328883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
    Pachocki CJ; Hol EM
    J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
    DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
    J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas.
    Noon A; Galban S
    Neoplasia; 2023 Jun; 40():100899. PubMed ID: 37030112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology, Diagnostic Strategies, and Therapeutic Advances in Diffuse Midline Glioma.
    Miguel Llordes G; Medina Pérez VM; Curto Simón B; Castells-Yus I; Vázquez Sufuentes S; Schuhmacher AJ
    J Clin Med; 2023 Aug; 12(16):. PubMed ID: 37629304
    [No Abstract]   [Full Text] [Related]  

  • 20. Fulminant hemorrhagic course of a thalamic H3 K27-altered diffuse midline glioma in an adult patient: illustrative case.
    Poletti N; Marques LL; Deigendesch N; Soleman J; Mariani L; Guzman R; Rychen J
    J Neurosurg Case Lessons; 2024 Jan; 7(4):. PubMed ID: 38252930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.